Cargando…
The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature
AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804040/ https://www.ncbi.nlm.nih.gov/pubmed/36184822 http://dx.doi.org/10.1111/cns.13983 |
_version_ | 1784862014476124160 |
---|---|
author | Ornowska, Marlena Wormsbecker, Andrew Andolfatto, Gary Leung, Tim S. Khan, Idan Medvedev, George |
author_facet | Ornowska, Marlena Wormsbecker, Andrew Andolfatto, Gary Leung, Tim S. Khan, Idan Medvedev, George |
author_sort | Ornowska, Marlena |
collection | PubMed |
description | AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac arrest. This search was performed once in May 2020, and an updated search was conducted in May 2021 and March 2022. RESULTS: All searches combined retrieved 181 results; no clinical trials were identified. As such, the authors were limited to writing a scoping review of the literature rather than a systematic review. CONCLUSIONS: The current state of the literature describes the mechanism of action of ketamine as a neuroprotective agent through its action as an NMDA antagonist. There is evidence of its efficacy as a neuroprotective agent in preclinical models of cardiac arrest. Current published clinical work supports the use of ketamine ameliorating neurologic outcomes in other conditions such as epilepsy, traumatic brain injury, and depression. The current state of the literature is reflective of the notion that the use of ketamine following cardiac arrest may result in improved neurologic outcomes. Future research directions should focus on the use of ketamine as a possible clinical intervention following cardiac arrest. |
format | Online Article Text |
id | pubmed-9804040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98040402023-01-04 The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature Ornowska, Marlena Wormsbecker, Andrew Andolfatto, Gary Leung, Tim S. Khan, Idan Medvedev, George CNS Neurosci Ther Original Articles AIMS: The objective of this article is to summarize the state of the literature surrounding the use of ketamine as a neuroprotective agent following cardiac arrest. METHODS: Five electronic databases were used to search for studies related to the use of ketamine for neuroprotection following cardiac arrest. This search was performed once in May 2020, and an updated search was conducted in May 2021 and March 2022. RESULTS: All searches combined retrieved 181 results; no clinical trials were identified. As such, the authors were limited to writing a scoping review of the literature rather than a systematic review. CONCLUSIONS: The current state of the literature describes the mechanism of action of ketamine as a neuroprotective agent through its action as an NMDA antagonist. There is evidence of its efficacy as a neuroprotective agent in preclinical models of cardiac arrest. Current published clinical work supports the use of ketamine ameliorating neurologic outcomes in other conditions such as epilepsy, traumatic brain injury, and depression. The current state of the literature is reflective of the notion that the use of ketamine following cardiac arrest may result in improved neurologic outcomes. Future research directions should focus on the use of ketamine as a possible clinical intervention following cardiac arrest. John Wiley and Sons Inc. 2022-10-02 /pmc/articles/PMC9804040/ /pubmed/36184822 http://dx.doi.org/10.1111/cns.13983 Text en © 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ornowska, Marlena Wormsbecker, Andrew Andolfatto, Gary Leung, Tim S. Khan, Idan Medvedev, George The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title | The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title_full | The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title_fullStr | The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title_full_unstemmed | The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title_short | The use of ketamine as a neuroprotective agent following cardiac arrest: A scoping review of current literature |
title_sort | use of ketamine as a neuroprotective agent following cardiac arrest: a scoping review of current literature |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804040/ https://www.ncbi.nlm.nih.gov/pubmed/36184822 http://dx.doi.org/10.1111/cns.13983 |
work_keys_str_mv | AT ornowskamarlena theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT wormsbeckerandrew theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT andolfattogary theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT leungtims theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT khanidan theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT medvedevgeorge theuseofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT ornowskamarlena useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT wormsbeckerandrew useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT andolfattogary useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT leungtims useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT khanidan useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature AT medvedevgeorge useofketamineasaneuroprotectiveagentfollowingcardiacarrestascopingreviewofcurrentliterature |